Dr. Choueiri on the Research With Immunotherapy in RCC

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

There is ongoing research investigating patients who progressed on prior immunotherapy regimens and received cabozantinib (Cabometyx). Those patients experienced a beneficial response with cabozantinib compared to everolimus, states Choueiri.